Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 17;47(4):282.
doi: 10.3390/cimb47040282.

Molecular Mechanisms and Potential Therapeutic Targets of Ischemia-Reperfusion Injury in Kidney Transplantation

Aaron J Huang  1 , Gaurav K Sharma  2 , Rohan Parikh  2 , Zhaosheng Jin  3 , Frank S Darras  1 , Sergio D Bergese  3
Affiliations
Review

Molecular Mechanisms and Potential Therapeutic Targets of Ischemia-Reperfusion Injury in Kidney Transplantation

Aaron J Huang et al. Curr Issues Mol Biol. .

Abstract

End-stage renal disease (ESRD) is a serious and lethal disease that carries with it a high morbidity and mortality rate if left untreated. Treating ESRD is conducted via renal replacement therapy and/or kidney transplantation, with the latter being the preferred option given the better outcomes and quality of life for the patients. However, as ESRD rises in prevalence, kidney transplantation rates remain largely unchanged. In every kidney transplantation, ischemia-reperfusion injury (IRI) is inevitable and the effect this has on the kidney depends based on donor type. IRI works through a variety of molecular mechanisms, primarily mitochondrial oxidative stress and programmed cell death mechanisms. Given the urgency to ensure the best outcomes for these limited kidney transplants, there has been a continued effort to find various potential therapeutic mechanisms to counteract IRI preoperatively, intraoperatively, and postoperatively. These include hypothermic machine perfusion, ischemic conditioning, nanoparticle removal of free radicals, peptide-based therapies, microRNA, and more. There is an ongoing effort to find the best way to mitigate IRI in kidney transplantation and this is being achieved through a better understanding of the molecular mechanisms of IRI.

Keywords: donor; end-stage renal disease; graft; inflammation; ischemia; kidney transplant; machine perfusion; reperfusion injury.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest. This study did not require or receive any funding.

Figures

Figure 1
Figure 1
Potential therapeutic strategies to ameliorate ischemia–reperfusion injury in kidney transplantation.
See this image and copyright information in PMC

References

    1. NKF Patient Education Team Kidney Failure. [(accessed on 8 April 2025)]. Available online: https://www.kidney.org/kidney-topics/patient-education-library-brochures.
    1. Thurlow J.S., Joshi M., Yan G., Norris K.C., Agodoa L.Y., Yuan C.M., Nee R. Global Epidemiology of End-Stage Kidney Disease and Disparities in Kidney Replacement Therapy. Am. J. Nephrol. 2021;52:98–107. doi: 10.1159/000514550. - DOI - PMC - PubMed
    1. Dor A., Pauly M.V., Eichleay M.A., Held P.J. End-stage renal disease and economic incentives: The International Study of Health Care Organization and Financing (ISHCOF) Int. J. Health Care Financ. Econ. 2007;7:73–111. doi: 10.1007/s10754-007-9024-9. - DOI - PubMed
    1. United States Renal Data System 2022 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. [(accessed on 8 April 2025)]; Available online: https://usrds-adr.niddk.nih.gov/2022.
    1. Ortiz A., Covic A., Fliser D., Fouque D., Goldsmith D., Kanbay M., Mallamaci F., Massy Z.A., Rossignol P., Vanholder R., et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet. 2014;383:1831–1843. doi: 10.1016/S0140-6736(14)60384-6. - DOI - PubMed

LinkOut - more resources